When a low-dose tablet is developed from a 6-dehydronandrolone acetate 17β-ester, the first processing bottleneck is not chemical potency but dry powder content uniformity of a cohesive, low-dosed active. A pharma-grade API batch received with a moisture content above 0.5% w/w should be rejected or vacuum-dried at 25–30°C before use because the acetate ester hydrolyses in the presence of free water during later wet massing. The tableting blend is formulated at 2–10% w/w active, with microcrystalline cellulose 30–50% w/w, lactose monohydrate 25–40% w/w, crospovidone or sodium starch glycolate 2–5% w/w, and magnesium stearate 0.5–1.0% w/w. The active should not be pre-blended with strongly alkaline powdered excipients such as anhydrous sodium carbonate because base-catalysed transesterification can generate free 19-nortestosterone-related impurities. A high-shear granulator with a bowl capacity of 100–300 L and an impeller tip speed of 4–6 m/s is used for wet massing; purified water or a 3–5% w/w povidone K30 binder solution is added to reach 8–12% w/w added water. The wet granules are dried in a fluid-bed dryer at inlet air temperature 45–55°C until loss on drying is 1.5–2.5% w/w, milled through a 0.8 mm conical screen, and lubricated for 2–3 minutes. Compression on a rotary press at 30–50 rpm with main compression force 8–14 kN produces tablets with breaking force 60–90 N and friability below 0.5% per USP <1216>. The finished film-coated tablet receives a 3–4% w/w polyvinyl alcohol-based aqueous film coat. Uniformity is assessed by USP <905>, dissolution by USP <711> in a validated surfactant-containing medium at 0.5–2.0% w/w sodium lauryl sulfate, and degradation products by ICH Q2(R1)-validated HPLC. Because stability data for this 6-ene ester in solid oral dosage forms are limited, forced degradation studies under ICH Q1A should bracket pH, oxidation, and photolysis before the finished dosage specification is fixed.

Why Does Capsule Filling Demand Tighter Bulk Density Control Than Tablet Compression?

Capsule filling on tamping pin machines forms powder plugs under a piston stroke; therefore, a stable tapped density and narrow particle size distribution determine die fill and fill weight variation more directly than in rotary tablet compression. For hard gelatin or HPMC capsules containing the acetate ester, the blend should be engineered to a bulk density between 0.45 g/mL and 0.60 g/mL, a tapped density between 0.55 g/mL and 0.75 g/mL, a Carr index of 15–25%, and an angle of repose below 35°. A representative fill formulation is 2–10% w/w active, 40–60% w/w lactose monohydrate, 25–40% w/w microcrystalline cellulose, 2–4% w/w croscarmellose sodium, and 0.25–0.5% w/w magnesium stearate. The lubricant mixing time is maintained below 3 minutes to reduce surface over-coating of the active and delayed dissolution. A production tamping pin machine with 1 or 3 tamping stations is operated at 30,000–120,000 capsules/hour; fill mass is monitored gravimetrically to a target weight tolerance of ±2.0%. The final filled capsule is sealed with a band or liquid encapsulation system when shell moisture is 7–9% w/w, because lower shell moisture increases brittleness and higher shell moisture can increase acetate hydrolysis risk. Potency and purity are verified by USP <905> and ICH Q2(R1)-validated HPLC, while dissolution is tested with USP <711> apparatus 2 at 50 rpm in a surfactant-containing aqueous medium. The terminal capsule is packaged in cold-form aluminium blister to reduce oxygen and moisture ingress; an oxidising headspace can attack the 6-ene double bond.

Fluid-bed top spray granulation as a particle size re-engineering step for oral granules

For granules intended for unit-dose sachets or dispersible oral use, simple dry blending is inadequate because segregation during filling can shift active content. The acetate ester is therefore granulated in a fluid-bed top spray system with copovidone at 3–5% w/w as binder dissolved in water or a water-ethanol mixture. The inlet air temperature is held at 45–60°C, the product bed temperature at 28–34°C, and the spray rate is set so that droplet diameter remains below 50 µm to avoid overwetting and local ester hydrolysis. The target granule size after sieving is 150–425 µm, with fines below 75 µm not more than 10% w/w and coarse material above 710 µm not more than 5% w/w. A representative formulation is 1–5% w/w active, 50–70% w/w mannitol or sucrose, 10–20% w/w microcrystalline cellulose, 3–5% w/w copovidone, 1–2% w/w sodium carboxymethylcellulose as dispersibility aid, and 0.5–1.0% w/w silicon dioxide as flow glidant. The final granules are filled into aluminium foil sachets under a nitrogen flush. Dissolution is controlled by granule disintegration rather than tablet matrix erosion; USP <711> basket method at 100 rpm is used for release testing. Moisture content is limited to 2.0% w/w by Karl Fischer titration to protect the ester bond. Because the granule is not compressed, the critical process parameter is binder spray pause time, not compression force. Full-scale batch data for this derivative are sparse, so a process analytical technology arrangement with near-infrared moisture monitoring is required at production scale.

Oil vehicle selection, terminal sterilisation margins, and viscosity limits in depot injection manufacturing

Oil-based injectable manufacturing for the 6-dehydronandrolone acetate ester imposes two simultaneous constraints: water content must remain below 0.2% w/w to limit ester hydrolysis, and bioburden after compounding must be low enough to allow aseptic filtration or terminal heat treatment. A typical intramuscular depot formulation contains 50–200 mg/mL active, 2.0–3.0% v/v benzyl alcohol, 10–20% v/v benzyl benzoate, and a pharmacopoeial oil such as sesame oil or medium-chain triglycerides. The oil is first heated to 40–50°C under nitrogen to reduce viscosity; the active is dissolved with a high-torque overhead stirrer; the solution is then cooled to 25°C and filtered through a 0.45 µm prefilter followed by a 0.22 µm sterilising-grade membrane. If the solution viscosity exceeds 150 mPa·s at 25°C, filtration flux may fall below commercially acceptable throughput. Viscosity can be reduced by raising benzyl benzoate content or using medium-chain triglycerides instead of castor oil. Terminal sterilisation at 121°C for 15 minutes should be introduced only after forced degradation data demonstrate no increase in free nandrolone-related hydrolysis products; otherwise, aseptic filling with pre-sterilised filter equipment is mandatory. The prefilled Type I glass vial is closed with a PTFE-coated bromobutyl rubber stopper under a nitrogen headspace. The finished oil solution is tested for particulate matter per USP <788>, sterility per USP <71>, bacterial endotoxins per USP <85>, and subvisible particles per USP <787>. Syringeability is evaluated using a 21-gauge needle under manual pressure because the injection is intramuscular.

The oil should be tested for peroxide value below 5 meq/kg, free fatty acids below 0.1% w/w, and water below 0.1% w/w before use. Polyunsaturated oils with high iodine values can promote oxidation of the 6-ene ring; α-tocopherol at 0.05–0.1% w/w may be added as antioxidant. Avoid contact with copper or iron components because transition metals accelerate peroxide formation.

Aqueous intramuscular suspension manufacture changes the particle size specification from oral granules to injectable micronized powder. The 6-dehydronandrolone acetate active is reduced to a laser diffraction D[v,0.9] below 10 µm, with D[v,0.5] between 2 µm and 4 µm, because larger crystals can block a 21-gauge needle. Wet bead milling with yttrium-stabilized zirconium oxide beads of 0.3–0.5 mm is preferred over dry micronization because the process can be run under aseptic conditions and reduces triboelectric agglomeration. A representative suspension is 50 mg/mL active, 0.1–0.2% w/w polysorbate 80 as wetting agent, 1.0% v/v benzyl alcohol as preservative, 10 mM sodium phosphate buffer at pH 6.0–7.0, and water for injection q.s. The acetate ester is unstable at strongly alkaline pH; the suspension should not be buffered above pH 7.5 because free-base hydrolysis accelerates and residual ester may fall below specification. The milled suspension is filled aseptically into Type I siliconized borosilicate vials. Terminal steam sterilisation is avoided unless specifically validated, since the aqueous phase at 121°C may hydrolyse the acetate group and raise free nandrolone-related impurities above ICH Q3B thresholds. Particulate matter is controlled per USP <788>; small-volume parenterals must show no more than 6,000 particles ≥10 µm and 600 particles ≥25 µm per container. Syringeability, subvisible particle counts per USP <787>, sterility per USP <71>, and endotoxin per USP <85> complete the release panel. The suspension should be stored at 2–8°C until long-term ICH Q1A stability data support room-temperature storage.

When Lyophilisation Replaces Ready-to-Use Oil Solution for Heat-Labile Injectable Units

If aqueous suspension or oil solution stability shows pH- or heat-dependent hydrolysis of the 6-ene acetate, a lyophilised cake becomes the alternate injectable route. The pre-lyophilisation solution is prepared at 25–100 mg/vial active, with mannitol 3–5% w/v and sucrose 1–2% w/v as lyoprotectants, and 5–10 mM citrate or phosphate buffer at pH 6.0–7.0. The solution is filtered through a 0.22 µm membrane into depyrogenated Type I glass vials. Freezing is performed to -40°C at a ramp rate not exceeding 0.5°C/min to avoid cryo-concentration and phase separation of the active. Primary drying is held at -20°C to -10°C under 100–150 mTorr; secondary drying is ramped to 25–35°C for 6–12 hours. The cake is stoppered under vacuum or nitrogen. Residual moisture by Karl Fischer titration per USP <921> is controlled below 1.0% w/w because moisture remaining in the cake accelerates hydrolysis after reconstitution. The terminal product is reconstituted with water for injection or a co-solvent diluent ampoule before intramuscular administration. Sterility per USP <71>, subvisible particles per USP <787>, and particulate limits per USP <788> are applied. Freeze-drying cycle models based on commercial nandrolone esters cannot be directly transferred; therefore, comparative pressure measurement and Pirani capacitance manometer data are used to confirm primary drying endpoint rather than fixed time alone.